Press Releases

10 Sep 2019

ProBioGen licenses GlymaxX® Technology to Bayer

read more ProBioGen licenses GlymaxX® Technology to Bayer

download PDF

23 May 2019

ProBioGen and Abcuro signed GlymaxX®-Improved Cell Line Development and GMP Production Agreement

read more ProBioGen and Abcuro signed GlymaxX®-Improved Cell Line Development and GMP Production Agreement

download PDF

15 May 2019

ProBioGen and Vaccitech Sign License Agreement for ProBioGen’s Technology Platform

read more ProBioGen and Vaccitech Sign License Agreement for ProBioGen’s Technology Platform

download PDF

07 May 2019

ESACT Inaugural Innovation Award to honor ProBioGen’s CSO Dr. Volker Sandig

read more ESACT Inaugural Innovation Award to honor ProBioGen’s CSO Dr. Volker Sandig

download PDF

22 Jan 2019

CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel In Vivo Delivery Technologies

read more CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel In Vivo Delivery Technologies

download PDF

03 Jan 2019

ProBioGen’s GlymaxX® ADCC Enhancement Technology used by Betta Pharmaceuticals

read more ProBioGen’s GlymaxX® ADCC Enhancement Technology used by Betta Pharmaceuticals

download PDF

06 Nov 2018

ProBioGen Announces Successful Bispecific GlymaxX® Development Project for Zymeworks

read more ProBioGen Announces Successful Bispecific GlymaxX® Development Project for Zymeworks

download PDF

10 Jul 2018

ProBioGen and Pionyr Immunotherapeutics Initiate a Second Immuno-Oncology Contract Development and Manufacturing Project

read more ProBioGen and Pionyr Immunotherapeutics Initiate a Second Immuno-Oncology Contract Development and Manufacturing Project

download PDF

26 Jun 2018

ProBioGen and Nouscom Sign License Agreement for ProBioGen’s Technology Platform

read more ProBioGen and Nouscom Sign License Agreement for ProBioGen’s Technology Platform

download PDF

24 May 2018

ProBioGen Announces Further Development Milestone for Use of Its GlymaxX® Cancer Cell-Killing Enhancement Antibody Technology with Merus N.V.

read more ProBioGen Announces Further Development Milestone for Use of Its GlymaxX® Cancer Cell-Killing Enhancement Antibody Technology with Merus N.V.

download PDF

Page 1 of 6

1
2
3
4
5
6
Next
Last »